Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of CBA-1205 in Advanced Solid Tumors
NCT06636435Phase 1Recruiting
- Sponsor
- Chiome Bioscience Inc.
- Start
- Jun 2020
- Primary completion
- Jun 2027
- Modality
- Naked Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cba-1205 in solid tumor, hepatocellular carcinoma (HCC), Malignant Melanoma (MM) and 1 more (5 arms), sponsored by Chiome Bioscience Inc. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 12 months. Started Jun 2020; status: recruiting.
02
Drugs
cba-1205
03
Conditions
solid tumorhepatocellular carcinoma (HCC)Malignant Melanoma (MM)pediatric cancer
Beyond the preview
Go deeper on NCT06636435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636435.